D.E. Shaw & Co
CTIC

D.E. Shaw & Co’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

D.E. Shaw & Co’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-34,578
Closed -$201K – 5596
2022
Q3 		$201K Sell
34,578
-69,261
-67% -$432K ﹤0.01% 4474
2022
Q2 		$620K Buy
+103,839
New +$532K ﹤0.01% 3973
2020
Q3 		– Sell
-13,207
Closed -$15K – 4366
2020
Q2 		$15K Buy
+13,207
New +$13.9K ﹤0.01% 3942
2019
Q4 		– Sell
-21,396
Closed -$18K – 4318
2019
Q3 		$18K Buy
21,396
+10,094
+89% +$7.71K ﹤0.01% 3758
2019
Q2 		$10K Hold
11,302
– – ﹤0.01% 3628
2019
Q1 		$11K Hold
11,302
– – ﹤0.01% 3545
2018
Q4 		$8K Hold
11,302
– – ﹤0.01% 3716
2018
Q3 		$24K Buy
+11,302
New +$28K ﹤0.01% 3677
2017
Q1 		– Sell
-2,326
Closed -$9K – 3810
2016
Q4 		$9K Sell
2,326
-930
-29% -$3.86K ﹤0.01% 3403
2016
Q3 		$12K Buy
3,256
+1,930
+146% +$7.03K ﹤0.01% 3339
2016
Q2 		$5K Buy
+1,326
New +$6.08K ﹤0.01% 3317
2016
Q1 		– Sell
-1,549
Closed -$19K – 4088
2015
Q4 		$19K Buy
1,549
+405
+35% +$5.41K ﹤0.01% 3745
2015
Q3 		$17K Sell
1,144
-1,262
-52% -$21.8K ﹤0.01% 3685
2015
Q2 		$47K Sell
2,406
-1,579
-40% -$30.5K ﹤0.01% 3692
2015
Q1 		$72K Buy
3,985
+440
+12% +$9.9K ﹤0.01% 3546
2014
Q4 		$84K Sell
3,545
-486
-12% -$11.2K ﹤0.01% 3918
2014
Q3 		$98K Buy
+4,031
New +$105K ﹤0.01% 3984
2014
Q2 		– Sell
-1,237
Closed -$42K – 4881
2014
Q1 		$42K Sell
1,237
-41,509
-97% -$1.42M ﹤0.01% 4206
2013
Q4 		$821K Sell
42,746
-8,715
-17% -$159K ﹤0.01% 3341
2013
Q3 		$843K Sell
51,461
-52,805
-51% -$612K ﹤0.01% 3187
2013
Q2 		$1.09M Buy
+104,266
New +$1.22M ﹤0.01% 2634

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

D.E. Shaw & Co's CTIC Position: Q4 2022 in Review

D.E. Shaw & Co sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2022, closing a stake of 34,578 shares — an estimated $201K sold.

D.E. Shaw & Co first reported a position in CTIC in Q2 2013 and held it in 21 quarters. The position peaked at $1.09M in Q2 2013. 145 funds tracked by Wall St. Rank hold CTIC as of Q4 2022.

  • D.E. Shaw & Co reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 34,578 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2022, an estimated $201K.
  • D.E. Shaw & Co first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 21 quarters.
  • D.E. Shaw & Co's CTI BioPharma Corp. (DE) Common Stock position peaked at $1.09M in Q2 2013.
  • 145 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.